<DOC>
	<DOCNO>NCT00442676</DOCNO>
	<brief_summary>Preeclampsia hypertensive disorder pregnancy lead cause fetal maternal morbidity mortality . Recent finding indicate preeclampsia inflammatory disorder associate increased expression COX-2 . This study test hypothesis treatment woman COX-2 inhibitor , celecoxib , stop inflammatory process reverse symptom preeclampsia .</brief_summary>
	<brief_title>Clinical Trial COX-2 Inhibitor Treatment Women With Preeclampsia</brief_title>
	<detailed_description />
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Pregnant woman preeclampsia 20 32 week gestation . Preeclampsia define maternal blood pressure &gt; 140/90 mmHg two reading least 6 hour apart proteinuria &gt; 300 mg/24 hour . Exclusion criterion include patient know sensitivity celecoxib ; patient demonstrate allergictype reaction sulfonamide ; patient experience asthma , urticaria , allergictype reaction take aspirin NSAIDs . Other exclusion criterion include patient know cardiovascular disease risk factor cardiovascular disease , prior history ulcer disease GI bleeding , impaired renal function , liver dysfunction . Exclusion criterion also include concomitant use oral corticosteroid , anticoagulant , diuretic , ACE inhibitor , aspirin , fluconazole , lithium .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>